首页> 外文期刊>Journal of infection and chemotherapy: official journal of the Japan Society of Chemotherapy >Risk factors of multidrug-resistant, extensively drug-resistant and pandrug-resistant Acinetobacter baumannii ventilator-associated pneumonia in a Medical Intensive Care Unit of University Hospital in Thailand
【24h】

Risk factors of multidrug-resistant, extensively drug-resistant and pandrug-resistant Acinetobacter baumannii ventilator-associated pneumonia in a Medical Intensive Care Unit of University Hospital in Thailand

机译:泰国大学医院的医疗重症监护室中多重耐药,广泛耐药和泛耐药的鲍曼不动杆菌呼吸机相关性肺炎的危险因素

获取原文
获取原文并翻译 | 示例
       

摘要

Ventilator-associated pneumonia (VAP) caused by Acinetobacter baumannii remains a significant cause of morbidity and mortality. Increasing antimicrobial resistance influences the selection of antibiotic treatment especially pandrug-resistant A. baumannii. A retrospective cohort study was conducted in the Medical Intensive Care Unit to identify the risk factors of VAP caused by multidrug-resistant A. baumannii (MDR-AB), extensively drug-resistant A. baumannii (XDR-AB) and pandrug-resistant A. baumannii (PDRAB). All 337 adult patients with confirmed A. baumannii VAP were included. The incidence of MDR-AB, XDR-AB and PDR-AB were 72 (21.4%), 220 (65.3%) and 12 (3.6%), respectively. The risk factor for MDR-AB was prior use of carbapenems (OR 5.20; 95% CI 1.41-19.17). Risk factors for XDR-AB were the prior use of carbapenems (OR, 6.30; 95% CI, 1.80-21.97) and a high Sequential Organ Failure Assessment (SOFA) score (OR 1.35; 95% CI 1.07-1.71). In PDR-AB, the risk factors were the prior use of colistin (OR, 155.95; 95% CI, 8.00-3041.98), carbapenems (OR, 12.84; 95% CI, 1.60-103.20) and a high Simplified Acute Physiology Score (SAPS II) (OR 1.10; 95% CI 1.01-1.22). In conclusion, previous exposure to antibiotics and severity of VAP were risk factors of drug-resistant A. baumannii. Judicious use of carbapenems and colistin is recommended to prevent the antimicrobial-resistant strains of this organism. (C) 2015, Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
机译:鲍曼不动杆菌引起的呼吸机相关性肺炎(VAP)仍然是发病率和死亡率的重要原因。抗菌素耐药性的提高会影响抗生素治疗的选择,尤其是耐潘多菌的鲍曼不动杆菌。在医疗重症监护室进行了一项回顾性队列研究,以确定由多重耐药性鲍曼不动杆菌(MDR-AB),广泛耐药性鲍曼不动杆菌(XDR-AB)和耐泛药性A引起的VAP危险因素鲍曼氏菌(PDRAB)。包括所有337例确诊鲍曼不动杆菌VAP的成年患者。 MDR-AB,XDR-AB和PDR-AB的发生率分别为72(21.4%),220(65.3%)和12(3.6%)。 MDR-AB的危险因素是先使用碳青霉烯类药物(OR 5.20; 95%CI 1.41-19.17)。 XDR-AB的危险因素是先前使用碳青霉烯类药物(OR,6.30; 95%CI,1.80-21.97)和较高的序贯器官衰竭评估(SOFA)评分(OR 1.35; 95%CI 1.07-1.71)。在PDR-AB中,危险因素是事先使用大肠菌素(OR,155.95; 95%CI,8.00-3041.98),碳青霉烯(OR,12.84; 95%CI,1.60-103.20)和较高的简化急性生理学分数( SAPS II)(OR 1.10; 95%CI 1.01-1.22)。总之,以前接触抗生素和VAP的严重程度是耐药鲍曼不动杆菌的危险因素。建议明智地使用碳青霉烯和大肠菌素,以防止这种生物的抗药性。 (C)2015年,日本化学治疗学会和日本传染病协会。由Elsevier Ltd.出版。保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号